Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMINRKW)

• Drug Name: Clomipramine Drug Info
• Synonyms: Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Obsessive compulsive disorder	6B20	Approved	[2]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 2801
  ChEBI ID: CHEMBL415
  CAS Number: CAS 303-49-1
  TTD Drug ID: DMINRKW
  VARIDT Drug ID: DR00476
  ACDINA Drug ID: D00139

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[10]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[11]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[12]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[13]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[14]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[15]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[16]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[12]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[12]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[12]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[17]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[19]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[20]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[19]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[21]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[23]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[24]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[25]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[26]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[27]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[28]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[29]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[30]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[29]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[25]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[31]

Drug(s) Affected By Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[32]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[33]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[8]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[39]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[8]

Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[41]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[42]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[42]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[43]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[44]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[46]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[8]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[6]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[48]

Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[49]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[8]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[51]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[52]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[37]

Drug(s) Affected By Protein DEPP1 (DEPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[8]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[54]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[8]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[8]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[55]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[56]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[8]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]

Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[8]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[8]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[61]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[61]
Haloperidol	DM96SE0	Delirium		Approved	[8]

Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[8]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Haloperidol	DM96SE0	Delirium		Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[62]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[6]

Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[5]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[5]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[63]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[65]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[61]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]

Drug(s) Affected By Stearoyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[9]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[9]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[41]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[9]
Fructose	DM43AN2	Vomiting	MD90	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[69]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[9]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[70]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[72]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[73]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[74]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[73]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[75]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[77]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[78]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[79]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[80]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[9]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[9]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[81]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[9]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[82]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[69]

Drug(s) Affected By Sodium-dependent serotonin transporter (SLC6A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[83]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[84]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[80]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[85]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[86]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[88]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Protein Interaction/Cellular Processes	[5]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[6]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[6]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Regulation of Drug Effects	[7]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Gene/Protein Processing	[8]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Gene/Protein Processing	[9]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[6]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Gene/Protein Processing	[8]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Gene/Protein Processing	[6]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Gene/Protein Processing	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2398).
• [2] Clomipramine FDA Label
• [3] Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13.
• [4] Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
• [5] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [6] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [7] Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13.
• [8] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [9] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [10] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [11] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [14] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [15] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [16] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [17] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [18] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [19] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [20] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [21] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [22] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [23] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [24] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [25] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [26] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [27] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [28] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [29] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [30] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [31] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [32] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [33] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [34] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [35] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [36] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [37] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [38] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [39] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [40] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [41] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [42] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [43] Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
• [44] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [45] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [46] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [47] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [48] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [49] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [50] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [51] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [52] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [53] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [54] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [55] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [56] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [57] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [58] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [59] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [60] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [61] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [62] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [63] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [64] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [65] Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
• [66] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [67] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [68] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [69] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [70] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [71] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [72] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [73] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [74] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [75] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [76] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [77] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [78] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [79] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [80] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [81] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [82] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [83] Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005 Nov 25;389(1):12-6. doi: 10.1016/j.neulet.2005.06.048.
• [84] Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
• [85] Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
• [86] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [87] Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
• [88] Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011 Sep 22;54(18):6305-18. doi: 10.1021/jm200682b. Epub 2011 Aug 23.
• [89] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.